Evaluated Data from 5 experiments.xlsx

Mass spectrometry (MS) based targeted
proteomic methods such as selected reaction monitoring (SRM) are emerging as a
promising tool for verification of candidate proteins in biological and
biomedical applications. The Clinical Proteomic Tumor Analysis Consortium
(CPTAC) of the National Cancer Institute has investigated the standardization
and analytical validation of the SRM assays and demonstrated robust analytical
performance on different instruments across different laboratories. An Assay
Portal has also been established by CPTAC to provide the research community a
resource consisting of large sets of targeted MS-based assays, and a depository
to share assays publicly. Herein, we report the development of 98 SRM assays
that have been thoroughly characterized according to the CPTAC Assay
Characterization Guidance Document; 37 of these passed all five experimental
tests. The assays cover 70 proteins previously identified at the protein level
in ovarian tumors. The experiments, methods and results for characterizing these
SRM assays for their MS response, repeatability, selectivity, stability, and endogenous
detection are described in detail. Data are available via PeptideAtlas,
Panorama and the CPTAC Assay Portal.